ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), Andrés Cervantes(INCLIVA Health Research Institute), Josep Tabernero(Deaconess Hospital), Dirk Arnold(Asklepios Klinik Altona), Sérgio Barroso(Hospital do Espírito Santo), Jarosław Reguła(Postgraduate School of Molecular Medicine), G. Bodoky(Unified Szent István and Szent László Hospital), Andrey Meshcheryakov(Russian Cancer Research Center NN Blokhin), Irıs D. Nagtegaal(Radboud University Nijmegen), Rob Glynne‐Jones(Mount Vernon Cancer Centre), Karin Haustermans(Radboud University Nijmegen), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Bengt Glimelius(Uppsala University), Timothy Price(Basil Hetzel Institute), Dan Aderka(Sheba Medical Center), Per Pfeiffer(University of Southern Denmark), Paulo M. Hoff(Translational Research in Oncology), Demetris Papamichail(Bank of Cyprus Oncology Center), Ioannis Souglakos(University of Crete), Geerard L. Beets(The Netherlands Cancer Institute), Judith Balmañà(Vall d'Hebron Hospital Universitari), Alexander Stein(Universität Hamburg), Roberto Labianca(Ospedale Papa Giovanni XXIII), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Karin Jordan(Martin Luther University Halle-Wittenberg), J. Gallardo(Clínica Alemana), David J. Kerr(University of Oxford), Werner Scheithauer(Comprehensive Cancer Center Vienna), Serdar Turhal(Marmara University), C.-H. Köhne(Klinikum Oldenburg), Bernard Nordlinger(Académie Nationale de Médecine), A. Garin(Russian Cancer Research Center NN Blokhin), Hesham El Ghazaly(Ain Shams University), Cornelis JH van de Velde(Leiden University), Vincenzo Valentini(Agostino Gemelli University Polyclinic), Jean‐Yves Douillard(Integrated Oncology (United States)), Alberto Sobrero(Ospedale Policlinico San Martino)
Cited by 1,533
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k